U.S. Food and Drug Administration Center for Drug Evaluation and ResearchSkip navigation

CDER - Center for Drug Evaluation and Research Logo

Drug Information

CDER Home Site Information Comments and Feedback What's New CDER Navigation Bar

CDER ArchivesSpecific AudiencesCDER CalendarRegulatory InformationDrug InformationAbout CDERSide Navigational Buttons

Doxycycline and Penicillin G Procaine for 
Inhalational Anthrax (Post-Exposure)


Doxycycline and penicillin G procaine are antibiotics used to treat bacterial infections in many different parts of the body. They do not work for viral infections (for example, the common cold). Doxycycline and penicillin G procaine have been approved for all forms of anthrax. (inhalational, gastrointestinal, and cutaneous). In October 2001, FDA published a Federal Register notice clarifying that these drugs were approved for inhalational anthrax (post-exposure). Use of doxycycline in children under 8 presents special concerns because of possible tooth discoloration. Long-term use of intravenous doxycycline or penicillin G procaine presents safety concerns, and patients should be switched, when appropriate, to other antibiotics to complete a 60 day course of therapy for inhalational anthrax (post-exposure).

Related Links from FDA

Background Information

For more information about doxycycline and penicillin G procaine, please contact the Division of Drug Information at druginfo@cder.fda.gov or 1-888-INFOFDA (463-6332).

totop.gif (1525 bytes) Back to Top   Back Drug Information


FDA/Center for Drug Evaluation and Research
Last Updated: June 18, 2003
Originator: OTCOM/DLIS
HTML by SJW